KRAS and pancreatic neoplasm: In an attempt to increase sensitivity, Cohen et al. [29] assessed the use of KRAS mutations in ctDNA in conjunction with elevated proteins in a study of 221 patients with only resectable pancreatic cancer (Stage I or II).